Multiple myeloma

The PBS subsidises lenalidomide and pomalidomide for patients with multiple myeloma.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lenalidomide and pomalidomide under section 100 of the National Health Act 1953, for patients with multiple myeloma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lenalidomide and pomalidomide.

Section 100 arrangements

Lenalidomide and pomalidomide

These items are only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

These items aren’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Lenalidomide

Initial treatment as monotherapy for newly diagnosed disease

Apply for initial authority approval to prescribe PBS subsidised lenalidomide to treat newly diagnosed multiple myeloma in writing and either:

All written applications must include the completed:

Initial treatment as dual therapy for newly diagnosed disease

Apply for initial authority approval to prescribe PBS subsidised lenalidomide as dual therapy to treat newly diagnosed multiple myeloma in writing and either:

All written applications must include the completed:

Initial treatment as triple therapy for newly diagnosed disease

Apply for initial authority approval to prescribe PBS subsidised lenalidomide as triple therapy to treat newly diagnosed multiple myeloma in writing and either:

All written applications must include the completed:

Initial treatment - progressive disease

Apply for initial authority approval to prescribe PBS subsidised lenalidomide to treat progressive multiple myeloma in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised lenalidomide to treat multiple myeloma can be made either:

Pomalidomide

Initial treatment as dual therapy

Apply for initial authority approval to prescribe PBS subsided pomalidomide as dual therapy to treat multiple myeloma in writing and either:

All written applications must include the completed:

Initial treatment as triple therapy

Apply for initial authority approval to prescribe PBS subsidised pomalidomide as triple therapy to treat multiple myeloma either:

Applying for continuing treatment

Application for continuing authority approval to prescribe PBS subsided pomalidomide to treat multiple myeloma can be made either:

Elotuzumab

Initial and continuing treatment as triple therapy

Applications for initial and continuing authority approval to prescribe PBS subsidised elotuzumab for triple therapy in combination with lenalidomide to treat relapsed and/or refractory multiple myeloma can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 May 2022